Premium
Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six‐year population‐based cohort analysis
Author(s) -
Zhou Jifang,
Han Jin,
Nutescu Edith A.,
Galanter William L.,
Walton Surrey M.,
Gordeuk Victor R.,
Saraf Santosh L.,
Calip Gregory S.
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15773
Subject(s) - medicine , hazard ratio , population , diabetes mellitus , incidence (geometry) , cohort , epidemiology , confidence interval , type 2 diabetes , cohort study , relative risk , endocrinology , physics , environmental health , optics
Summary Conflicting evidence exists on the epidemiology of type 2 diabetes mellitus (T2 DM ) among patients with sickle cell disease ( SCD ). This study measured the prevalence, incidence and clinical outcomes associated with T2 DM in a large US population of commercially‐insured adults aged ≥20 years with SCD between 2009 and 2014. Among 7070 patients with SCD , the mean age (median) was 39 (37) years and 60·8% were female. The standardized prevalence of T2 DM among patients with SCD showed a modest increase, from 15·7% to 16·5% ( P trend = 0·026), and was comparable to African‐American respondents to the National Health and Nutrition Examination Survey (18·2%). Over 17 024 person‐years, the crude incidence rate for T2 DM was 25·4 per 1000 person‐years. Incident T2 DM was associated with comorbid hypertension (hazard ratio [ HR ] = 1·45, 95% confidence interval [ CI ] 1·14–1·83), and dyslipidaemia ( HR = 1·43, 95% CI 1·04–1·96). Compared to SCD patients without T2 DM , more SCD patients with T2 DM had diagnoses of nephropathy (28·0% vs. 9·5%; P < 0·001), neuropathy (17·7% vs. 5·2%; P < 0·001) and stroke (24·1% vs. 9·2%; P < 0·001). Prevalence of T2 DM in SCD patients is similar to the general African American population with an increasing trend in recent years. These trends support routine screening for T2 DM in aging patients with SCD , especially those with comorbid hypertension and/or dyslipidaemia.